History
- 2018. 08
- AIMEDBIO Inc. was founded
- 2019. 01
- In-licensed the patents and resources
from Samsung Medical Center
- 2019. 08
- AVATAMED PTE Ltd., a spin-off company
from A-star founded in Singapore
- 2019. 12
- AIMEDBIO R&D Center OPEN
- 2020. 04
- Genotwin, a spin-off company from
Columbia University founded in New York
- 2020. 06
- AIMEDBIO initiates a joint lab with CBMED
to collaborate on precision medicine drug
screening project
- 2020.09
- Licensed-in a brain-specific payload from
Samsung Medical Center & Sejong University
- 2021.05.
- Strategic Investment from Yuhan Corporation
- 2021.11.
- AMB302, a novel ADC potentially active in
brain cancer therapy, to receive grant from
Korea Drug Development Fund (KDDF)
- 2022.04.
- Co-development agreement signed with
GeneQuantum Healthcare Co., Ltd., for AMB302,
a First-in-Class therapeutic ADC
- 2022.11.
- Antibody therapeutics for solid cancer,
AMB018, selected as a Korea Drug
Development Fund (KDDF) Project
- 2023.06.
- Co-development agreement signed with
GeneQuantum Healthcare Co., Ltd., to
collaborate on maximum of five ADCs
- 2023.07.
- AMB001, an immune modulating
antibody targeting inflammatory reactions,
selected for KDDF funding
- 2023.09.
- AIMEDBIO receives
Samsung Life Science Fund's first domestic investment to
collaborate on ADC toolbox co-development.
- 2024.07.
- Series B funding round closed.
